Arcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research report sent to investors on Wednesday, MarketBeat Ratings reports. Needham & Company LLC currently has a $20.00 price target on the stock. ARQT has been the topic of several other research reports. Mizuho lifted their […]
Needham & Company LLC reissued their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research report sent to investors on Wednesday, MarketBeat Ratings reports. Needham & Company LLC currently has a $20.00 price target on the stock. ARQT has been the topic of several other research reports. Mizuho lifted their […]
